Brief: Alkermes Receives FDA Fast Track Designation For Nemvaleukin Alfa For The Treatment Of Mucosal Melanoma
02/08/2021 12:11
Aug 2 (Reuters) - Alkermes Plc ALKS.O :
* ALKERMES RECEIVES FDA FAST TRACK DESIGNATION FOR
NEMVALEUKIN
ALFA FOR THE TREATMENT OF MUCOSAL MELANOMA
Source text for Eikon: ID:nPnbPH7Jma
Further company coverage: ALKS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alkermes
See all newsBrief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
Brief: Alkermes Announces Effectiveness Of Mural Oncology Form 10 Registration Statement
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 Net Income USD 47.8 Million